FDA Declines Approval for Lung Cancer Drug Ivonescimab
Regulatory authorities have turned down the lung cancer therapy ivonescimab, developed by Summit Therapeutics and Akeso, citing a lack of demonstrated overall survival benefit.
🧠Mind & Mental HealthPhoto: statnews.com
Key points
- The FDA rejected the lung cancer treatment ivonescimab.
- Developers Summit Therapeutics and Akeso were notified via a formal letter.
- Regulators cited a lack of proven overall survival benefit despite delayed disease progression.
Regulatory Decision on Ivonescimab
The U.S. Food and Drug Administration has issued a complete response letter declining approval for ivonescimab, a targeted treatment for a specific form of lung cancer developed jointly by U.S.-based Summit Therapeutics and Chinese pharmaceutical firm Akeso. According to the companies, regulatory reviewers determined that although the therapy demonstrated an ability to slow the progression of the disease, it failed to show that patients lived longer as a result.
Agency reviewers concluded that this absence of an overall survival benefit meant the medication did not maintain a favorable benefit-risk profile required for clearance. Summit Therapeutics manages the development and commercialization rights for the drug outside of China, and company representatives noted that the regulatory hurdle, while significant, was not entirely unexpected.
What to know: Regulatory decisions rely heavily on demonstrable extensions in patient survival rates. Readers navigating oncology care options should consult qualified medical professionals for personalized guidance.
Source statnews.com — statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatme… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.